![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0012.png)
allied
academies
Page 45
Notes:
July 05-06, 2019 | Paris, France
Pharmaceutics and Advanced Drug Delivery Systems
2
nd
International Conference and Exhibition on
Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN:2249-622X | Volume 9
Mechanistic modeling: the pathway to precision medicine
V A Shiva Ayyadurai
CytoSolve, Inc, USA
T
here is a growing and critical need for integrating
molecular systems science with computation to model
complex disease processes for accelerating drug discovery,
drug repurposing, validation of complementary and
alternative medicine (CAM) therapies, and identification of
efficacious multi-combination therapeutics, while ensuring
a personalized and precise medicine. Such needs cannot be
advanced without collaborative integration of knowledge
across biological disciplines. This talk will share the recent
successes, through multiple case studies, in the use of
CytoSolve, a computational systems biology collaboratory,
developed at MIT., that provides an integrative approach to
address these critical needs. Previous approaches, largely
based on statistical techniques, have been unscalable
and largely useless to scientists who seek to understand
complex biological mechanisms. CytoSolve’s successes
have been published in peer-reviewed journals and have
received recognition in Nature for its potential to develop
multi-combination therapies. These successes including:
FDA allowance for a multi-combination pancreatic cancer
therapeutic; theDepartment of Defense (DoD) and theUnited
States Pharmacopeia (USP) understanding of toxicity and
adverse reaction multi-combination nutritional supplements;
and, modeling of rare diseases in orphan drug domains such
as Neuromyelitis Optica (NMO) and Hereditary Angioedema
(HAE) have inspired major nutraceutical researchers, cancer
centers such as MD Anderson, National Cancer Institute
and others to explore the use of CytoSolve for integrating
CytoSolve’s collaboratory with modern in vitro and in vivo
methods to accelerate the development of multicombination
therapeutics. This talk that will provide an introduction to a
disruptive platform that will likely revolutionize development
of therapeutics in the 21st century.
e
:
vashivaoffice@vashiva.com